Hello, Reader. For all that artificial intelligence has accomplished over the last few years, one thing it has not yet ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market Perform on Tuesday, boosting sales ...

Bristol Myers rallied, adding about 10% as fears about the AbbVie drug's competitive threat to its Cobenfy franchise, which it acquired as part of a $14 billion buyout of Karuna Therapeutics.

Pharmaceutical company AbbVie announced that an experimental schizophrenia drug that was key to its $8.7 billion acquisition ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...

Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...